H

    HUTCHMED DRC (HCM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $12.12
    -0.26 (-2.10%)

    Market Cap: $2.15B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(21/28)
    Avg Surprise
    +107.10%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$N/AN/AN/ABeat-
    Mar 26
    		$N/AN/AN/ABeat-
    Dec 25
    		$N/A$0.25N/ABeat-
    Sep 25
    		$0.00$0.00N/ABeat-
    Jun 25
    		$0.52$0.00N/ABeat-
    Mar 25
    		$0.00$0.00N/ABeat-
    Dec 24
    		$0.01N/A-75.00%Miss+101.4%
    Sep 24
    		$0.00$0.00N/ABeat-
    Jun 24
    		$0.00$0.00N/ABeat-100.0%
    Mar 24
    		$0.00$0.00N/ABeat-
    Dec 23
    		$-0.70$-1.08+35.19%Beat+31.4%
    Sep 23
    		$0.00N/A-100.00%Miss-
    Jun 23
    		$0.97$-0.06+1863.64%Beat+201.0%
    Mar 23
    		$0.00N/A+100.00%Beat+100.0%
    Dec 22
    		$-1.02$-1.02+0.00%Beat-3300.0%
    Sep 22
    		$0.00N/A+100.00%Beat-
    Jun 22
    		$-0.96$-0.72-33.33%Miss-140.0%
    Mar 22
    		$-0.70$-0.70+0.00%Beat-102.3%
    Dec 21
    		$-0.03N/A+76.92%Beat+0.0%
    Sep 21
    		$0.00N/A+100.00%Beat+100.0%
    Jun 21
    		$-0.40$-0.07-471.43%Miss-1233.3%
    Mar 21
    		$-0.35$-0.36+3.35%Beat-30.5%
    Dec 20
    		$-0.03N/A+76.92%Beat+88.0%
    Sep 20
    		$-0.18$-0.21+10.09%Beat-43.4%
    Jun 20
    		$-0.03N/A+83.33%Beat+80.6%
    Mar 20
    		$-0.27$-0.32+17.13%Beat-784.0%
    Dec 19
    		$-0.25$-0.23-8.70%Miss-2400.0%
    Sep 19
    		$-0.13$-0.17+24.29%Beat-83.9%
    Jun 19
    		$-0.15$-0.15-3.13%Miss-10.5%
    Mar 19
    		$-0.03N/A+76.92%Beat+78.6%
    Dec 18
    		$-0.01N/A+83.33%Beat-200.0%
    Sep 18
    		$-0.07$-0.07+0.00%Beat-800.0%
    Jun 18
    		$-0.14$-0.16+12.50%Beat-1500.0%
    Mar 18
    		$-0.14$-0.16+12.50%Beat-240.0%
    Dec 17
    		$0.01$0.01+0.00%Beat+0.0%
    Jun 17
    		$0.01N/A-85.71%Miss-
    Mar 17
    		$0.01$0.00N/ABeat-
    Dec 16
    		$0.10$-0.01+1100.00%Beat-
    Sep 16
    		$0.01$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio15.15EV/EBITDA1.68x
    Price/FCF212.67xFCF Yield0.47%
    Profitability
    Profit Margin3.26%Operating Margin0.31%
    ROE1.46%ROIC1.31%
    Financial Health
    Debt/Equity0.02xInterest Coverage24.21x
    Current Ratio5.64xQuick Ratio5.50x
    Trading Statistics
    Beta0.44Avg Volume63.22K
    52-Week High$18.3052-Week Low$9.77

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.41
    SMA 20$12.29
    SMA 50$11.51
    SMA 200$13.27
    EMA 10$12.31
    EMA 20$12.18
    EMA 50$11.91
    EMA 200$13.05

    MACD

    Line: 0.22Signal: 0.28Hist: -0.06

    ADX

    ADX: 17.2+DI: 32.2-DI: 29.9

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down12.0
    PSAR$12.82

    Bollinger Bands

    Upper Band$12.94
    Lower Band$11.64
    %B Position1055%(Upper)
    Band Width0.37

    RSI (14-Day)

    Neutral
    51.3

    Momentum Oscillators

    Stoch %K33.9
    Stoch %D40.8
    Williams %R-86.7
    ROC (10d)-3.5%
    Momentum-0.44
    CCI (20d)-20.6
    MFI (14d)31.7

    Volatility Measures

    ATR (14d)$0.30(2.4%)
    StdDev (20d)0.32
    Hist Vol30.5%(Moderate)

    Volume Flow

    VWAP$12.22
    OBV1.3M
    AD Line1.8K
    CMF (20d)-0.011

    Volume Metrics

    Avg Vol (20d)62.3K
    Vol Ratio1.1x
    VWMA (20d)$12.41

    Pivot Points

    R3$12.60
    R2$12.54
    R1$12.46
    Pivot Point$12.40
    S1$12.32
    S2$12.26
    S3$12.18

    Advanced Oscillators

    TSI17.42
    Ultimate Osc37.3
    KST95.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$139.14M$139.14M$135.42M$135.42M$138.84M$138.84M$162.26M$162.26M$152.84M$152.84M$152.56M$80.25M
    Cost of Revenue$115.47M$115.47M$158.53M$158.53M$83.79M$83.79M$190.43M$190.43M$90.07M$90.07M$239.06M$166.75M
    Gross Profit$23.67M$23.67M$-23,116,000$-23,116,000$55.05M$55.05M$-28,169,000$-28,169,000$62.77M$62.77M$-86,499,500$-86,499,500
    Operating Expenses$23.24M$23.24M$-5,293,000$-5,293,000$56.81M$56.81M$-20,077,000$-20,077,000$76.53M$76.53M$-39,860,000$-39,860,000
    R&D$39.39M$39.39M$41.38M$41.38M$35.99M$35.99M$59.05M$59.05M$47.63M$47.63M$79.21M$79.21M
    SG&A$15.90M$15.90M$19.49M$19.49M$13.88M$13.88M$16.92M$16.92M$15.23M$15.23M$5.76M$18.97M
    Operating Income$434,500$434,500$-17,823,000$-17,823,000$-1,757,000$-1,757,000$-8,092,000$-8,092,000$-13,760,500$-13,760,500$-46,639,500$-46,639,500
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$8.73M$8.73M$1.31M$1.31M$259.36M$259.36M$8.16M$8.16M$14.53M$14.53M$-33,297,500$-33,297,500
    Income Tax Expense$604,500$604,500$224,000$224,000$31.58M$31.58M$2.15M$2.15M$1.44M$1.44M$889,500$889,500
    Net Income$7.96M$7.96M$977,500$977,500$227.48M$227.48M$5.96M$5.96M$12.90M$12.90M$-33,885,500$-33,885,500
    EBITDA$3.97M$3.97M$-14,228,000$-14,228,000$1.30M$1.30M$-5,047,000$-5,047,000$-10,634,500$-10,634,500$-44,442,000$-44,442,000
    EBIT$434,500$434,500$-17,823,000$-17,823,000$-1,757,000$-1,757,000$-8,092,000$-8,092,000$-13,760,500$-13,760,500$-46,639,500$-46,639,500
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HCM

    News

    HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case

    HUTCHMED (China) Limited has reported an update regarding its Chairman and Non-executive Director, Dr. Dan Eldar, following the insolvency of S.D. Sight Diagnostics Ltd., where he previously served as a director. The company clarifies that neither S.D. Sight nor Hutchison Water Israel E.P.C Ltd (which nominated Dr. Eldar) are part of the HUTCHMED Group, and the insolvency proceedings, involving about NIS3.1 million, do not impact HUTCHMED's businesses or operations. This disclosure is made solely to comply with AIM Rule 17 Schedule 2(g) due to Dr. Eldar's former directorship.

    Stock Titan•8/18/26•
    Neutral

    REG - Hutchmed China Ltd - Announcement pursuant to AIM Rule 17 Schedule 2(g)

    Hutchmed (China) Limited has announced an update regarding Dr. Dan Eldar, Chairman and Non-executive Director, in accordance with AIM Rule 17 Schedule 2(g). S.D. Sight Diagnostics Ltd., a company where Dr. Eldar previously served as a director, has entered insolvency proceedings in Israel. Hutchmed states that neither S.D. Sight nor Hutchison Water Israel E.P.C Ltd (which invested in S.D. Sight) are part of the Hutchmed Group, and the insolvency proceedings are not expected to impact Hutchmed's operations.

    TradingView•8/18/26•
    Neutral

    HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

    HUTCHMED announced positive results from the SAFFRON Phase III trial, showing that ORPATHYS® plus TAGRISSO® significantly improved progression-free and overall survival in patients with MET-driven EGFR-mutated non-small cell lung cancer after progression on TAGRISSO®. This combination provides a potential new biomarker-directed, all-oral treatment option for a patient population with high unmet needs. The safety profile was consistent with known profiles, and these data will be shared with regulatory authorities for global registrations.

    Yahoo Finance Singapore•8/17/26•
    Bullish

    HUTCHMED reports positive Phase 3 SAFFRON survival results

    HUTCHMED announced positive results from its Phase 3 SAFFRON trial, showing that ORPATHYS plus TAGRISSO significantly improved progression-free and overall survival for patients with EGFR-mutated advanced non-small cell lung cancer. The company plans to present the data at a medical meeting and seek regulatory registrations. Following the announcement, HUTCHMED's shares saw a slight increase in pre-market trading.

    grafa.com•8/17/26•
    Bullish

    Hutchmed shares rise 5% after positive Phase III lung cancer trial results

    HUTCHMED China's shares rose 5% following positive Phase III trial results for its lung cancer treatment, ORPATHYS, developed in combination with AstraZeneca's TAGRISSO. The trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and overall survival for patients with advanced or metastatic non-small cell lung cancer. This outcome is crucial as it addresses MET-driven resistance to EGFR-targeted treatments and could lead to broader global regulatory approvals for the drug combination.

    Investing.com Canada•8/17/26•
    Bullish

    Frequently Asked Questions About HCM

    Does HCM pay dividends?
    HUTCHMED DRC (HCM) does not currently pay a regular dividend.
    What is HCM's P/E ratio?
    HUTCHMED DRC has a price-to-earnings (P/E) ratio of 15.15.
    What is HCM's market cap?
    HUTCHMED DRC (HCM) has a market capitalization of $2.15B with a current stock price of $12.12.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In